I copy news articles pertaining to research, news and information for Parkinson's disease, Dementia, the Brain, Depression and Parkinson's with Dystonia. I also post about Fundraising for Parkinson's disease and events. I try to be up-to-date as possible. I have Parkinson's diseases as well and thought it would be nice to have a place where updated news is in one place. That is why I began this blog.
I am not responsible for it's contents, I am just a copier of information searched on the computer. Please understand the copies are just that, copies and at times, I am unable to enlarge the wording or keep it uniformed as I wish. This is for you to read and to always keep an open mind.
Please discuss this with your doctor, should you have any questions, or concerns. Never do anything without talking to your doctor. I do not make any money from this website. I volunteer my time to help all of us to be informed. Please No advertisers, and No Information about Herbal treatments. This is a free site for all.
Monday, July 10, 2017
New technology to manipulate cells could one day help treat Parkinson's, arthritis, other diseases
DNA strands in materials act like traffic signals to start, stop cell activity or regenerate tissue
Instructing cells with programmable DNA-peptide hybrids: Switching bioactivity on and off
A groundbreaking advancement in materials from Northwestern University could potentially help patients requiring stem cell therapies for spinal cord injuries, stroke, Parkinson’s disease, Alzheimer’s disease, arthritic joints or any other condition requiring tissue regeneration, according to a new study.
“It’s important in the context of cell therapies for people to cure these diseases or regenerate tissues that are no longer functional,” said senior author Samuel I. Stupp, director of Northwestern’s Simpson Querrey Institute for BioNanotechnology and Board of Trustees Professor of Materials Science and Engineering, Chemistry, Medicine and Biomedical Engineering.
Cells in our bodies are constantly being signaled with many types of instructions coming from proteins and other molecules present in the matrices that surround them. For example, these can be cues for cells to express specific genes so they can proliferate or differentiate into several types of cells leading to growth or regeneration of tissues. One of the marvels of this signaling machinery is the built-in capacity in living organisms to make signals stop and re-start as needed, or to switch off one signal and activate a different one to orchestrate very complex processes. Building artificial materials with this type of dynamic capacity for regenerative therapies has been virtually impossible so far.
New technology could be useful in therapies using patient-derived stem cells to regenerate tissue
The new work published today reports the development of the first synthetic material that has the capability to trigger reversibly this type of dynamic signaling. The platform could not only lead to materials that manage stem cells for more effective regenerative therapies, but will also allow scientists to explore and discover in the laboratory new ways to control the fate of cells and their functions.
One of the findings is the possibility of using the synthetic material to signal neural stem cells to proliferate, then at a specific time selected by the operator, trigger their differentiation into neurons and then return the stem cells back to a proliferative state on demand.
The paper also reports that spinal cord neural stem cells, initially grouped into structures known as “neurospheres,” can be driven to spread out and differentiate using a signal. But when this signal is switched off, the cells spontaneously re-group themselves into colonies. This uncovers strong interactions among these cells that could be important in understanding developmental and regenerative cues.
Stem cell proliferation and differentiation can be triggered over multiple cycles with new materials technology
The potential use of the new technology to manipulate cells could help cure a patient with Parkinson’s disease. The patient’s own skin cells could be converted to stem cells using existing techniques. The new technology could help expand the newly converted stem cells in vitro – in the lab – and then drive their differentiation into dopamine-producing neurons before transplantation back to the patient.
In the new technology, materials are chemically decorated with different strands of DNA, each designed to display a different signal to cells. To activate signals to cells, soluble molecules containing complementary DNA strands coupled to peptides are added to the material to create DNA double helices displaying the signal. By adding a few drops of the DNA-peptide conjugate, a green light is given to produce more stem cells. The approach to provide the material with dynamic intelligence is to expose the surface to a soluble single-stranded DNA molecule designed to “grab” the signal-containing strand of the duplex and form a new DNA double helix. This new duplex is no longer attached to the material surface and washes away, thus switching the biological signal off. To turn the signal back on, all that is needed is to now introduce a new copy of single-stranded DNA bearing a signal that will reattach to the material’s surface.
“People would love to have cell therapies that utilize stem cells derived from their own bodies to regenerate tissue,” Stupp said. “In principle, this will eventually be possible, but one needs procedures that are effective at expanding and differentiating cells in order to do so. Our technology does that.”
Starting or stopping cell activity existed before; this research discovered how to re-start and stop again cell activity several times
While this process is currently only done in vitro with the vision of then transplanting cells, Stupp said in the future it might be possible to perform this process in vivo. The stem cells would be implanted in the clinic, encapsulated in the type of material described in the new work, via an injection and targeted to a particular spot. Then the soluble molecules would be given to the patient to manipulate proliferation and differentiation of transplanted cells.
The research was carried out at Northwestern’s Simpson Querrey Institute for BioNanotechnology. The National Institute of Dental and Craniofacial Research of the National Institutes of Health (grant 5R01DE015920) provided funding for biological experiments, and the U.S. Department of Energy, Office of Science, Basic Energy Sciences provided funding for the development of the new materials (grants DE-FG01-00ER45810 and DE-SC0000989 supporting an Energy Frontiers Research Center on Bio-Inspired Energy Science (CBES)).
The paper is titled “Instructing cells with programmable peptide DNA hybrids.” Samuel I. Stupp is the senior author of the paper, post-doctoral fellows Ronit Freeman and Nicholas Stephanopoulos (now assistant professor at Arizona State University) are primary authors, and post-doctoral fellow Zaida Alvarez-Pinto is co-author of the study.